Paper Details 
Original Abstract of the Article :
BACKGROUND: With its reported side effects Desvenlafaxine succinate (DSV) is a good candidate to prepare prolonged release system. Such prolonged release could decrease the rapid DSV absorption after oral administration and reduce its exaggerated side effects. METHODS: A prolonged release Desvenlaf...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/27211103

データ提供:米国国立医学図書館(NLM)

Desvenlafaxine Succinate: A Tale of Controlled Release

This study delves into the world of drug delivery systems, focusing on the development of a prolonged-release formulation for desvenlafaxine succinate (DSV), an antidepressant medication. The authors propose a multilayered particulate system using ionotropic gelation, a technique that creates tiny beads encapsulating the drug. They meticulously optimized the formulation variables, including pH, DSV: polymer ratio, cross-linker concentration, and curing time, to achieve optimal drug entrapment. The researchers evaluated the release profile of the optimized formulation using an everted sac technique, demonstrating a prolonged release pattern similar to the innovator drug. This suggests that the developed system could potentially mitigate the side effects associated with rapid DSV absorption after oral administration.

A Journey Through the Desert of Drug Delivery

This study highlights the challenges and successes of developing controlled-release formulations for medications. Imagine a camel caravan traversing a desert, each camel representing a different drug molecule. A controlled-release system, like a clever oasis, acts as a reservoir, releasing the drug molecules gradually over time, minimizing side effects and ensuring a smoother journey.

A Promise for Improved Treatment

This study offers hope for improving the treatment of conditions using DSV. By developing a prolonged-release formulation, the authors aim to reduce the side effects associated with rapid drug absorption. This could lead to better patient outcomes and improved compliance with medication regimens.

Dr. Camel's Conclusion

This study showcases the development of a promising prolonged-release formulation for desvenlafaxine succinate. This innovative drug delivery system could potentially mitigate the side effects associated with rapid absorption, leading to improved patient outcomes. As we continue to explore the desert of drug delivery, finding new and effective ways to administer medications remains a crucial goal for improving patient care.

Date :
  1. Date Completed 2018-05-07
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27211103

DOI: Digital Object Identifier

CDD-EPUB-75875

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.